---
title: 'Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders
  (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS).
  Part II: Attack therapy and long-term management'
date: '2023-09-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37676297/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230907180928&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: This manuscript presents practical recommendations for managing acute
  attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum
  disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in
  the central nervous system (CNS), primarily affecting the optic nerves, spinal cord,
  and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention
  to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G
  ...
disable_comments: true
---
This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G ...